<DOC>
	<DOCNO>NCT00276796</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , topotecan , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give paclitaxel together topotecan cisplatin work treat patient advance , persistent , recurrent cervical cancer .</brief_summary>
	<brief_title>Paclitaxel , Topotecan , Cisplatin Treating Patients With Advanced , Persistent , Recurrent Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Estimate antitumor activity combination paclitaxel , topotecan , cisplatin patient advance , persistent , recurrent carcinoma cervix . - Determine nature degree toxicity drug regimen patient . Secondary - Determine duration progression-free survival overall survival . - Determine impact prior chemoradiation response treatment . OUTLINE : This open-label study . Patients receive paclitaxel IV 1 hour follow topotecan IV 30 minute cisplatin IV 1 hour day 1 8 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 66 patient accrue study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Advanced , persistent , recurrent squamous nonsquamous cell carcinoma cervix document disease progression Histologic confirmation original primary tumor required Disease must measurable least one dimension conventional technique , include palpation , plain xray , CT scan , MRI Measurable disease define least one lesion accurately measure Each lesion must ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan Tumors within previously irradiate field designate `` nontarget '' lesion unless progression document biopsy obtain confirm persistence ≥ 90 day completion radiation therapy PATIENT CHARACTERISTICS : GOG performance status 02 Platelet count ≥ 100,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN SGOT alkaline phosphatase ≤ 2.5 time ULN Neuropathy ( sensory motor ) ≤ grade 1 No active infection require antibiotic No evidence one malignancy present within past 5 year Nonmelanoma skin cancer allow Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior therapy cytotoxic drug advance recurrent cervical carcinoma Prior cisplatin radiosensitizer primary treatment disease allow No previous cancer treatment contraindicate study treatment No prior radiotherapy portion abdominal cavity pelvis except treatment cervical cancer No prior chemotherapy abdominal pelvic tumor except treatment cervical cancer Recovered effect recent surgery , radiotherapy , therapy At least 4 week since prior radiotherapy More 3 year since prior radiotherapy localize cancer breast , head neck , skin free recurrent metastatic disease More 3 year since prior adjuvant chemotherapy localize breast cancer provide patient free recurrent metastatic disease No hormonal therapy direct malignant tumor within past week Concurrent hormone replacement therapy permit No concurrent amifostine protective reagent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
	<keyword>cervical small cell carcinoma</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
</DOC>